Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Repeated measurement of lipoprotein(a): technical versus biological variability.

Atherosclerosis·2025
Same author

Treatment-Associated Neuroplastic Changes in People with Stroke-Associated Ataxia-An fMRI Study.

Neurology international·2025
Same author

Bone remodelling after scaphoid fractures: HR-pQCT, clinical and laboratory data from a prospective 1-year follow-up study.

Bone·2024
Same author

Lipoprotein(a) concentrations and cardiovascular disease in patients with chronic kidney disease: Results from the German Chronic Kidney Disease study.

Journal of internal medicine·2024
Same author

Identification of regulatory networks and crosstalk factors in brown adipose tissue and liver of a cold-exposed cardiometabolic mouse model.

Cardiovascular diabetology·2024
Same author

Advancements in risk stratification and management strategies in primary cardiovascular prevention.

Atherosclerosis·2024
Same journal

Macrophage-Specific SPP1 Contributes to Pressure Overload-Induced Cardiac Dysfunction and Maladaptive Remodeling.

JACC. Basic to translational science·2026
Same journal

Increased Arrhythmic Risk in Obesity Is Transduced by Adipose Tissue-Derived Extracellular Vesicles.

JACC. Basic to translational science·2026
Same journal

Cardiac Impulse Propagation: An Integrated View.

JACC. Basic to translational science·2026
Same journal

Recognizing Early Career Translational Investigators.

JACC. Basic to translational science·2026
Same journal

Simplified and Refined Murine Model of Reversible Aortic Constriction for Characterizing Cardiac Functional Recovery.

JACC. Basic to translational science·2026
Same journal

Atrial Fibrillation Beyond the Atrium.

JACC. Basic to translational science·2026
See all related articles

Related Experiment Videos

Mendelian Randomization Reveals Interleukin-6 Receptor-Lipoprotein(a) Interplay With Independent Cardiovascular Risk

Azin Kheirkhah1, Silvia Di Maio1, Stefan Coassin1

  • 1Institute of Genetic Epidemiology, Medical University of Innsbruck, Innsbruck, Austria.

JACC. Basic to Translational Science
|May 8, 2026
PubMed
Summary
This summary is machine-generated.

Interleukin-6 receptor (IL-6R) signaling causally influences Lp(a) levels, a cardiovascular disease risk factor. Considering IL-6R

Keywords:
Mendelian randomizationcardiovascular diseaseinterleukin-6 receptorlipoprotein(a)

Related Experiment Videos

Area of Science:

  • Genetics and Cardiovascular Disease Research
  • Molecular Biology and Biomarkers

Background:

  • Cardiovascular disease (CVD) remains a leading cause of mortality globally.
  • Interleukin-6 receptor (IL-6R) signaling and lipoprotein(a) [Lp(a)] are implicated as causal risk factors for CVD.
  • The precise relationship between IL-6R signaling, IL-6 levels, and Lp(a) concentrations requires elucidation.

Purpose of the Study:

  • To investigate the causal effect of IL-6R signaling on Lp(a) concentrations using Mendelian randomization.
  • To examine whether the functional state of IL-6R confounds the association between IL-6 and Lp(a).
  • To assess the independent and combined effects of IL-6R signaling and Lp(a) on CVD risk.

Main Methods:

  • Two-sample Mendelian randomization (MR) was employed to assess the causal effect of IL-6R signaling on Lp(a).
  • Epidemiological analyses using UK Biobank data were conducted to evaluate confounding effects.
  • Factorial MR was utilized to determine the independent contributions of IL-6R signaling and Lp(a) to CVD risk.

Main Results:

  • Mendelian randomization provided evidence for a causal effect of IL-6R signaling on Lp(a) concentrations.
  • Epidemiological analyses revealed that the functional state of IL-6R can confound the IL-6 and Lp(a) association.
  • The direct effect of circulating IL-6 on Lp(a) was modest, even when accounting for IL-6R status.
  • Factorial MR indicated that reduced IL-6R signaling and lower Lp(a) independently decrease CVD risk.

Conclusions:

  • IL-6R signaling exerts a causal influence on Lp(a) concentrations, highlighting a direct interplay between these CVD risk factors.
  • Accounting for IL-6R functional state is crucial to avoid confounding the association between IL-6 and Lp(a).
  • Independent down-regulation of IL-6R signaling and Lp(a) present complementary strategies for cardiovascular disease risk reduction.